Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Arthritis & Rheumatism2012Vol. 64(4), pp. 1215–1226
Citations Over TimeTop 1% of 2012 papers
Brad H. Rovin, Richard Furie, Kevin Latinis, R. John Looney, Fernando C. Fervenza, Jorge Sánchez‐Guerrero, Romeo Maciuca, David Zhang, Jay Garg, Paul Brunetta, Gerald B. Appel, LUNAR Investigator Group
Abstract
Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.
Related Papers
- → Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome(2015)43 cited
- → Cyclophosphamide in lupus nephritis(2005)36 cited
- [Cyclophosphamide bolus therapy in lupus nephritis--status of the clinical study].(1993)
- → Therapeutic Trials in Lupus Nephritis(1991)9 cited
- [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].(2002)